



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**July 15, 2014 6:00 – 8:15 p.m.**  
**\*\*\* Please note new times \*\*\***

- 1. Executive Session** **6:00 - 6:15**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
  
- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**  
(Public Comment Prior to Board Action)
  
- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:30**
  - Pharmacy Trend CY 2013
  - Updates
  
- 4. Medical Director Update** **6:30 - 6:35**
  - Clinical Programs Update
  - Prescriber Comments
  
- 5. Follow-up Items from Previous Meetings** **6:35 – 6:35**
  - None
  
- 6. RetroDUR/DUR** **6:35 – 6:45**
  - Incretin Mimetics
  
- 7. Clinical Update: Drug Reviews** **6:45 – 7:40**  
(Public comment prior to Board action)

**Abbreviated New Drug Reviews**

- Copaxone<sup>®</sup> (glatiramer acetate) Injection 40 mg/ml
- Xartemis<sup>®</sup> XR (oxycodone/acetaminophen) Oral Extended Release Tablet

**Full New Drug Reviews**

- Anoro Ellipta<sup>®</sup> (umeclidinium and vilanterol) Inhaler
- Aptiom<sup>®</sup> (eslicarbazepine acetate) Oral Tablet
- Farxiga<sup>®</sup> (dapagliflozin) Oral Tablet
- Luzu<sup>®</sup> (luliconazole 1%) Topical Cream
- Velphoro<sup>®</sup> (sucroferric oxyhydroxide) Oral Chewable Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **7:40 – 7:55**  
(Public comment prior to Board action)
- Multiple Sclerosis Agents
  - Second Generation Antipsychotics for Bipolar Depression (includes review of newer indication for Latuda<sup>®</sup> (lurasidone))
- 9. Clinical Update: New/Updated Clinical Guidelines** **7:55 – 7:55**  
(Public comment prior to Board action)
- None
- 10. New Managed Therapeutic Drug Classes** **7:55 – 7:55**  
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **7:55 – 7:55**  
(Public comment prior to Board action)
- None
- 12. General Announcements** **7:55– 8:15**  
**Selected FDA Safety Alerts**
- Olmesartan: FDA review of cardiovascular risks for diabetics taking hypertension drug not conclusive
  - OTC Acne Products: FDA warns of rare but serious hypersensitivity reactions with certain over-the-counter topical acne products
  - Testosterone Products: FDA adding general warning to testosterone products about potential for venous blood clots
- 13. Adjourn** **8:15**